F Zingone1,2, A Abdul Sultan1, C J Crooks1, L J Tata1, C Ciacci2, J West1. 1. Division of Epidemiology and Public Health, University of Nottingham, City Hospital, Nottingham, UK. 2. Coeliac center, Department of Medicine and Surgery, University of Salerno, Salerno, Italy.
Abstract
BACKGROUND: Patients with coeliac disease are considered as individuals for whom pneumococcal vaccination is advocated. AIM: To quantify the risk of community-acquired pneumonia among patients with coeliac disease, assessing whether vaccination against streptococcal pneumonia modified this risk. METHODS: We identified all patients with coeliac disease within the Clinical Practice Research Datalink linked with English Hospital Episodes Statistics between April 1997 and March 2011 and up to 10 controls per patient with coeliac disease frequency matched in 10-year age bands. Absolute rates of community-acquired pneumonia were calculated for patients with coeliac disease compared to controls stratified by vaccination status and time of diagnosis using Cox regression in terms of adjusted hazard ratios (HR). RESULTS: Among 9803 patients with coeliac disease and 101 755 controls, respectively, there were 179 and 1864 first community-acquired pneumonia events. Overall absolute rate of pneumonia was similar in patients with coeliac disease and controls: 3.42 and 3.12 per 1000 person-years respectively (HR 1.07, 95% CI 0.91-1.24). However, we found a 28% increased risk of pneumonia in coeliac disease unvaccinated subjects compared to unvaccinated controls (HR 1.28, 95% CI 1.02-1.60). This increased risk was limited to those younger than 65, was highest around the time of diagnosis and was maintained for more than 5 years after diagnosis. Only 26.6% underwent vaccination after their coeliac disease diagnosis. CONCLUSIONS: Unvaccinated patients with coeliac disease under the age of 65 have an excess risk of community-acquired pneumonia that was not found in vaccinated patients with coeliac disease. As only a minority of patients with coeliac disease are being vaccinated there is a missed opportunity to intervene to protect these patients from pneumonia.
BACKGROUND:Patients with coeliac disease are considered as individuals for whom pneumococcal vaccination is advocated. AIM: To quantify the risk of community-acquired pneumonia among patients with coeliac disease, assessing whether vaccination against streptococcal pneumonia modified this risk. METHODS: We identified all patients with coeliac disease within the Clinical Practice Research Datalink linked with English Hospital Episodes Statistics between April 1997 and March 2011 and up to 10 controls per patient with coeliac disease frequency matched in 10-year age bands. Absolute rates of community-acquired pneumonia were calculated for patients with coeliac disease compared to controls stratified by vaccination status and time of diagnosis using Cox regression in terms of adjusted hazard ratios (HR). RESULTS: Among 9803 patients with coeliac disease and 101 755 controls, respectively, there were 179 and 1864 first community-acquired pneumonia events. Overall absolute rate of pneumonia was similar in patients with coeliac disease and controls: 3.42 and 3.12 per 1000 person-years respectively (HR 1.07, 95% CI 0.91-1.24). However, we found a 28% increased risk of pneumonia in coeliac disease unvaccinated subjects compared to unvaccinated controls (HR 1.28, 95% CI 1.02-1.60). This increased risk was limited to those younger than 65, was highest around the time of diagnosis and was maintained for more than 5 years after diagnosis. Only 26.6% underwent vaccination after their coeliac disease diagnosis. CONCLUSIONS: Unvaccinated patients with coeliac disease under the age of 65 have an excess risk of community-acquired pneumonia that was not found in vaccinated patients with coeliac disease. As only a minority of patients with coeliac disease are being vaccinated there is a missed opportunity to intervene to protect these patients from pneumonia.
Authors: Tom van Gils; Petula Nijeboer; Jan Hein Tm van Waesberghe; Veerle Mh Coupé; Kiki Janssen; Jessy A Zegers; Shaikh A Nurmohamed; Georg Kraal; Sabine Ci Jiskoot; Gerd Bouma; Chris Jj Mulder Journal: United European Gastroenterol J Date: 2016-08-17 Impact factor: 4.623
Authors: Benjamin Lebwohl; Peter H R Green; Jonas Söderling; Bjorn Roelstraete; Jonas F Ludvigsson Journal: JAMA Date: 2020-04-07 Impact factor: 56.272
Authors: Giovanni A Roldan; Sehrish Jamot; Krzysztof Kopec; Amber Charoen; Daniel Leffler; Edward R Feller; Samir A Shah Journal: Dig Dis Sci Date: 2022-06-01 Impact factor: 3.199
Authors: Louise Emilsson; Benjamin Lebwohl; Peter Hr Green; Joseph A Murray; Karl Mårild; Jonas F Ludvigsson Journal: United European Gastroenterol J Date: 2017-04-24 Impact factor: 4.623
Authors: Jan Zirk-Sadowski; Jane A Masoli; Joao Delgado; Willie Hamilton; W David Strain; William Henley; David Melzer; Alessandro Ble Journal: J Am Geriatr Soc Date: 2018-04-20 Impact factor: 5.562
Authors: Jonas F Ludvigsson; Carolina Ciacci; Peter Hr Green; Katri Kaukinen; Ilma R Korponay-Szabo; Kalle Kurppa; Joseph A Murray; Knut Erik Aslaksen Lundin; Markku J Maki; Alina Popp; Norelle R Reilly; Alfonso Rodriguez-Herrera; David S Sanders; Detlef Schuppan; Sarah Sleet; Juha Taavela; Kristin Voorhees; Marjorie M Walker; Daniel A Leffler Journal: Gut Date: 2018-02-13 Impact factor: 23.059
Authors: Joseph Moneim; Hera Asad; Eman Butt; Jamil Shah Foridi; Yasmin Khan; Safwaan Patel; Jawad Qureshi; Ravi Thakar Journal: Prim Health Care Res Dev Date: 2019-10-30 Impact factor: 1.458